地尔硫卓对人乳腺癌症细胞阿霉素细胞毒性和细胞摄取的增强作用

IF 0.4 Q4 ONCOLOGY

Breast Cancer Management Pub Date : 2019-12-01 DOI:10.2217/bmt-2019-0018

Hamdan S Al-malky, Z. A. Damanhouri, Jumana Y Al Aama, A. A. Al Qahtani, W. Ramadan, H. Alkreathy, Sameer E Al Harthi, A. Osman

{"title":"地尔硫卓对人乳腺癌症细胞阿霉素细胞毒性和细胞摄取的增强作用","authors":"Hamdan S Al-malky, Z. A. Damanhouri, Jumana Y Al Aama, A. A. Al Qahtani, W. Ramadan, H. Alkreathy, Sameer E Al Harthi, A. Osman","doi":"10.2217/bmt-2019-0018","DOIUrl":null,"url":null,"abstract":"Aim: Breast cancer is the most common cancer among Arab women and also around the world. Chronic cardiotoxicity and multidrug resistance are potential limiting factors of doxorubicin (DOX), a known anthracycline antibiotic. Materials & methods: DOX cytotoxicity was evaluated by the sulforhodamine method. DOX cellular uptake, detection of P-glycoprotein activity and the photomicrograph of MCF-7 cells were also determined. Results: Diltiazem (DIL) treatment improved DOX cytotoxic activity and increased the cellular uptake of DOX significantly and aggregation of rhodamine 123, reflecting inhibition of P-glycoprotein pump. Cytopathological investigation of MCF-7 cells revealed marked cytotoxic activity of DOX in the presence of DIL. Conclusion: DIL treatment enhanced DOX cytotoxic effect and reduced multidrug resistance, which increased the drug accumulation intracellularly.","PeriodicalId":43086,"journal":{"name":"Breast Cancer Management","volume":" ","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/bmt-2019-0018","citationCount":"7","resultStr":"{\"title\":\"Diltiazem potentiation of doxorubicin cytotoxicity and cellular uptake in human breast cancer cells\",\"authors\":\"Hamdan S Al-malky, Z. A. Damanhouri, Jumana Y Al Aama, A. A. Al Qahtani, W. Ramadan, H. Alkreathy, Sameer E Al Harthi, A. Osman\",\"doi\":\"10.2217/bmt-2019-0018\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aim: Breast cancer is the most common cancer among Arab women and also around the world. Chronic cardiotoxicity and multidrug resistance are potential limiting factors of doxorubicin (DOX), a known anthracycline antibiotic. Materials & methods: DOX cytotoxicity was evaluated by the sulforhodamine method. DOX cellular uptake, detection of P-glycoprotein activity and the photomicrograph of MCF-7 cells were also determined. Results: Diltiazem (DIL) treatment improved DOX cytotoxic activity and increased the cellular uptake of DOX significantly and aggregation of rhodamine 123, reflecting inhibition of P-glycoprotein pump. Cytopathological investigation of MCF-7 cells revealed marked cytotoxic activity of DOX in the presence of DIL. Conclusion: DIL treatment enhanced DOX cytotoxic effect and reduced multidrug resistance, which increased the drug accumulation intracellularly.\",\"PeriodicalId\":43086,\"journal\":{\"name\":\"Breast Cancer Management\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2019-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2217/bmt-2019-0018\",\"citationCount\":\"7\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breast Cancer Management\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/bmt-2019-0018\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/bmt-2019-0018","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 7

摘要

目的:乳腺癌是阿拉伯妇女乃至全世界最常见的癌症。慢性心脏毒性和多重耐药是阿霉素(一种已知的蒽环类抗生素)的潜在限制因素。材料与方法:采用磺胺法评价DOX细胞毒性。测定DOX细胞摄取、p -糖蛋白活性检测和MCF-7细胞显微照片。结果:地尔硫卓(DIL)处理提高了DOX的细胞毒活性，显著增加了DOX的细胞摄取和罗丹明123的聚集，反映了p -糖蛋白泵的抑制。MCF-7细胞的细胞病理学研究显示，在DIL存在下，DOX具有显著的细胞毒活性。结论:DIL可增强DOX细胞毒作用，降低多药耐药，增加细胞内药物蓄积。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Diltiazem potentiation of doxorubicin cytotoxicity and cellular uptake in human breast cancer cells

Aim: Breast cancer is the most common cancer among Arab women and also around the world. Chronic cardiotoxicity and multidrug resistance are potential limiting factors of doxorubicin (DOX), a known anthracycline antibiotic. Materials & methods: DOX cytotoxicity was evaluated by the sulforhodamine method. DOX cellular uptake, detection of P-glycoprotein activity and the photomicrograph of MCF-7 cells were also determined. Results: Diltiazem (DIL) treatment improved DOX cytotoxic activity and increased the cellular uptake of DOX significantly and aggregation of rhodamine 123, reflecting inhibition of P-glycoprotein pump. Cytopathological investigation of MCF-7 cells revealed marked cytotoxic activity of DOX in the presence of DIL. Conclusion: DIL treatment enhanced DOX cytotoxic effect and reduced multidrug resistance, which increased the drug accumulation intracellularly.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Breast Cancer Management ONCOLOGY-

CiteScore

0.60

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Breast Cancer Management (ISSN: 1758-1923) addresses key issues in disease management by exploring the best patient-centered clinical research and presenting this information both directly, as clinical findings, and in practice-oriented formats of direct relevance in the clinic. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Breast Cancer Management provides oncologists and other health professionals with the latest findings and opinions on reducing the burden of this widespread disease. Recent research findings and advances clinical practice in the field are reported and analyzed by international experts. The journal presents this information in clear, accessible formats. All articles are subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal’s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3. Coverage includes: Diagnosis and imaging, Surgical approaches, Radiotherapy, Systemic therapies, Cancer clinical trials, Genetic aspects of disease, Personalized medicine, Translational research and biomarker studies, Management of psychological distress, Epidemiological studies, Pharmacoeconomics, Evidence-based treatment guidelines.